Open
Actively Recruiting
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
About
Brief Summary
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Plaque psoriasis for at least 6 months.
- Moderate to severe disease.
- Candidate for phototherapy or systemic therapy.
Exclusion Criteria:
- Other forms of psoriasis.
- History of recent infection.
- Prior exposure to TAK-279 or active comparator.
Other protocol defined inclusion/exclusion criteria apply.
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
23-5201
Category
Autoimmune Disorders
Principal Investigator
Contact
- Ross Divinagracia
Location
- UCLA Santa Monica
- UCLA Westwood